Predix Pharmaceuticals
Boston
About Predix Pharmaceuticals
Predix is a drug discovery and development company that uses a novel 3D Discovery and Optimization Engine for GPCR drug candidates and is taking its novel compounds into the clinic. The discovery engine uses a sophisticated proprietary algorithm, PREDICT(TM), for computer modeling the 3D structure of any GPCR target; advanced technologies HYPERION(TM) and RISS(TM) for rapid high-throughput in silico screening of millions of compounds against the 3D in silico model of the target; and an integrated medicinal/computational platform for lead optimization based on the receptor's structure (ICELR-3D(TM)) and predictive algorithms for important drug properties. In August, Predix and Physiome Sciences Inc. combined companies and expanded the expertise into ion channel drug discovery.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Total funding: $54.6M
- Funding stage: M&A
- Last round: Series C (Jan 2005)
- Ticker: nasdaq:PRDX
- Website: predixpharm.com
Industries & Categories
Health Care, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/predix-pharmaceuticals-1820610 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.